Colon cancer. A role for cyclo-oxygenase-2-specific nonsteroidal anti-inflammatory drugs

Drugs and Aging

Volumn 16, Issue 5, 2000, Pages 329-334

  Reddy, Bandaru S ^a   Rao, Chinthalapally V ^a  

^a AMERICAN HEALTH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2; IBUPROFEN; INDOMETACIN; KETOPROFEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; SULINDAC;

ADENOMATOUS POLYP; CANCER EPIDEMIOLOGY; CANCER INHIBITION; CANCER MODEL; CANCER PREVENTION; CLINICAL TRIAL; COLON CANCER; DIGESTIVE SYSTEM ULCER; DRUG EFFICACY; DRUG SPECIFICITY; EDITORIAL; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HUMAN; NEPHROTOXICITY; NONHUMAN; PRIORITY JOURNAL;

EID: 0034038772     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200016050-00002     Document Type: Editorial

References (35)

1. 1. World Health Organization. The World Health Report 1996. Geneva, World Health Organization, 1997
2. 2. Landis SH, Murray T, Bolden S, et al. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 9-31
3. 3. Wattenberg LW. Chemoprevention of cancer. Cancer Res 1985; 45: 1-8
4. 4. Potter JD, Steinmetz K. Vegetables, fruit and phytoestrogens as preventive agents. Publication no. 139, Lyon: International Agency for Research on Cancer Scientific Publications, 1996
5. 5. International Agency for Research on Cancer Handbooks of Cancer Prevention. Non-steroidal anti-inflammatory drugs. Vol. 1. Lyon: International Agency for Research on Cancer, 1997
6. 6. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Pt 1). J Natl Cancer Inst 1998; 90: 1529-36
7. 7. Kelloff GJ. Prospectives on cancer chemoprevention research and drug development. Adv Cancer Res 2000; 78: 199-334
8. 8. Thun MH, Namboodiri MM, Heath Jr CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6
9. 9. Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large bowel cancer. J Natl Cancer Inst 1991; 83: 355-8
10. 10. Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illness, operations and medications: case-control results from the Melbourne Colorectal Cancer Study. Cancer Res 1988; 48: 4399-404
11. 11. Waddel WR, Ganser GF, Cerise EJ, et al. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-9
12. 12. Narisawa T, Satoh M, Sano M, et al. Inhibition of initiation and promotion on N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroidal anti-inflammatory agent indomethacin. J Jpn Surg Soc 1998; 99: 362-7
13. 13. Pollard M, Luckert PH. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 1984; 25: 117-21
14. 14. Reddy BS, Rao CV, Rivenson A, et al. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993; 14: 1493-7
15. 15. Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-9
16. 16. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-6
17. 17. Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenomas in male health professionals. Ann Int Med 1994; 121: 241-6
18. 18. Greenberg ER, Baron JA. Prospects for preventing colorectal cancer. J Natl Cancer Inst 1993; 85: 1182-4
19. 19. Reddy BS, Maruyama H, Kelloft G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal anti-inflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987; 47: 5340-6
20. 20. Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a non-steroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72
21. 21. Wargovich MJ, Chem CD, Harris C, et al. Inhibition of aberrant crypt growth by non-steroidal anti-inflammatory agents and differentiation agents in the rat colon. Int J Cancer 1995; 60: 515-9
22. 22. Reddy BS, Tokumo K, Kulkarni N, et al. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992; 13: 1019-23
23. 23. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res 1998; 58: 409-12
24. MIn mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996; 56: 710-4
25. 25. Boolbol SK, Dannenberg AJ, Chadburn A, et al. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res 1996; 56: 2556-60
26. 26. Marnett LJ. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992; 52: 5575-89
27. 27. Eberhart CE, DuBois RN. Eicosanoids and the gastrointestinal tract. Gastroenterology 1995; 109: 285-301
28. 28. Kargman SL, O'Neill GP, Vickers PJ, et al. Expression of prostaglandin G/H synthase-1 and-2 protein in human colon cancer. Cancer Res 1995; 55: 2556-9
29. 29. DuBois RN, Radhika A, Reddy BS, et al. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996; 110: 1259-62
30. 30. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase-2. Cell 1995; 83: 493-501
31. Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 803-9
32. 32. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (Pt II). J Natl Cancer Inst 1998; 90: 1609-20
33. 33. Reddy BS, Rao CV, Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon cancer. Cancer Res 1996; 56: 4566-9
34. 34. Reddy BS, Hirose Y, Lubet R, et al. Chemoprevention of colon cancer by specific cyclooxygenase-2 inhibitor, celecoxib, administered during different stages of carcinogenesis. Cancer Res 2000 Jan 15; 60: 293-7
35. 35. Reddy BS. Novel approaches to the prevention of colon cancer by nutritional manipulation and chemoprevention. Cancer Epidemiol Biomarkers Prev 2000; 9: 239-47